reconstitute 5mg tirzepatide Compounded TIRZEPATIDE 5MG - Lyophilized

Plaintiffs claim manufacturers: Knew or should have known gastroparesis could be permanent Failed to adequately warn patients and doctors Understated the severity and duration of risk Continued aggressive marketing despite safety signals 2

It does not activate GIP

Quantifying the Market Impact: During the GLP-1 shortage (late 2022 to late 2024), the compounded market exploded

Managing work, family, and personal health can be difficult without the right support system in place

While individual case reports may exist, these do not establish causation, as patients taking Wegovy often have multiple risk factors for thrombosis independent of the medication